rs1058932 — CYP2C8

CYP2C8 3-prime UTR variant associated with cardiovascular risk via altered epoxyeicosatrienoic acid metabolism and hydroxychloroquine-related renal adverse effects

See your personal result for CYP2C8

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP2C8 3'-UTR — Where Drug Metabolism Meets Cardiovascular Biology

CYP2C8 is a cytochrome P450 enzyme that metabolizes approximately 5% of all drugs undergoing hepatic phase I oxidation — including the chemotherapy agent paclitaxel, the antidiabetics repaglinide and pioglitazone, and the antimalarials amodiaquine and hydroxychloroquine. Beyond drug metabolism, CYP2C8 plays a lesser-known but important role in converting arachidonic acid into [epoxyeicosatrienoic acids (EETs) | Lipid mediators produced by cytochrome P450 epoxygenases; they dilate coronary arteries, reduce vascular inflammation, and promote fibrinolysis], which are endogenous cardioprotective signalling molecules. The rs1058932 variant sits in the 3' untranslated region (3'-UTR) of CYP2C8 and has been linked to increased cardiovascular risk and altered drug tolerability.

The Mechanism

The CYP2C8 gene is located on chromosome 10q23.33 on the minus strand. rs1058932 is described in the coding-strand literature as C>T; on the [plus strand | Plus strand = forward/reference strand; what genome files report] reported in genome files this is G>A (reference G, alternate A). As a 3'-UTR variant, rs1058932 does not change the amino acid sequence of the enzyme. Instead, 3'-UTR polymorphisms can alter mRNA stability, polyadenylation efficiency, or microRNA binding — any of which can shift the steady-state level of CYP2C8 protein in hepatocytes and vascular endothelium. [| Kirchheiner et al. (PMID 18303964) demonstrated that CYP2C8 genotype moderately influences urinary dihydroxyeicosatrienoic acid excretion, confirming that genetic variation in CYP2C8 functionally alters arachidonic acid epoxygenase activity in humans]. Reduced CYP2C8 activity from the A allele would lower EET production, attenuating vasodilation and anti-inflammatory signalling in the coronary vasculature.

The Evidence

Cardiovascular risk: The best-powered evidence comes from the Rotterdam Study11 Rotterdam Study
Prospective population-based cohort; n=5,199 without prevalent MI at baseline, 290 incident MI events during follow-up. Carriers of the rs1058932 A allele (coded as T on the minus strand) had a hazard ratio of 1.54 (95% CI 1.22–1.95) for incident MI after Bonferroni correction. A significant gene–sex interaction was observed (relative excess risk 1.40; 95% CI 0.33–2.47), with the effect being strongest in men, suggesting that sex steroid pathways may modulate the EET-mediated vascular effect. The association was replicated in direction but not magnitude across other cohorts; not all studies have confirmed it, and the functional mechanism linking a 3'-UTR variant to reduced EET output requires further characterisation.

Hydroxychloroquine adverse effects: A prospective study in 146 patients with [systemic lupus erythematosus (SLE) | Autoimmune disease treated long-term with hydroxychloroquine; CYP2C8 participates in HCQ oxidative metabolism in vitro] and rheumatoid arthritis (RA) found that the AG heterozygous genotype carried significantly higher risk of renal dysfunction during hydroxychloroquine therapy versus AA + GG combined (P = 0.017). [| Gao et al., BMC Medical Genomics, 2022 (PMID 35135554); observational, single-centre, n=146; predominantly female, mean HCQ duration ~52 months]. This heterozygote-excess pattern is unusual and the study is small, so this finding warrants replication before clinical use.

Drug metabolism — broader substrates: Clinical pharmacogenetic studies of the major CYP2C8 functional alleles (*2 and *3) demonstrate substrate-specific effects on paclitaxel, repaglinide, and thiazolidinedione pharmacokinetics. [| Daily & Aquilante (PMID 19761371): comprehensive 2009 review of CYP2C8 clinical pharmacogenetics across drug classes]. Whether rs1058932 influences these same substrates is plausible via expression-level modulation but has not been tested directly in pharmacokinetic trials.

Practical Actions

The cardiovascular signal in males carrying the A allele justifies proactive lipid and vascular monitoring. For hydroxychloroquine users, the AG-genotype renal signal — while based on a single small study — warrants baseline creatinine assessment and periodic monitoring during long-term therapy. The variant's position in the 3'-UTR means it does not definitively alter CYP2C8 metabolizer phenotype in the CPIC star-allele framework, so standard prescribing for paclitaxel and repaglinide applies unless a patient also carries a coding-region allele (*2, *3, *4).

Interactions

rs1058932 co-segregates on the same chromosome with the major functional CYP2C8 coding alleles in some haplotypes. Individuals carrying both rs1058932 A and the CYP2C8*3 allele (rs11572080 + rs10509681) would have both expression-level and catalytic-level perturbations. The cardiovascular EET signal should be considered additive with CYP2J2 variants (rs10889160) in the epoxygenase pathway, as both enzymes contribute to vascular EET production.

Drug Interactions

hydroxychloroquine increased_toxicity literature
paclitaxel dose_adjustment literature
repaglinide dose_adjustment literature
pioglitazone dose_adjustment literature
rosiglitazone dose_adjustment literature
amodiaquine dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal CYP2C8 3'-UTR Normal

Common genotype — standard CYP2C8 expression

You carry two copies of the reference G allele at rs1058932. About 66% of people globally share this genotype (approximately 66% in Europeans). CYP2C8 expression and arachidonic acid epoxygenase activity are unaffected by this variant. No elevated cardiovascular or drug-toxicity risk is associated with this genotype.

AG Heterozygous Carrier Intermediate

One copy of the CYP2C8 3'-UTR risk variant

The AG genotype was specifically highlighted in the hydroxychloroquine study (PMID 35135554) because the risk was numerically higher in heterozygotes than in AA homozygotes — an unusual pattern that may reflect a dosage or haplotype-specific interaction rather than a simple additive effect. Until this is replicated in a larger cohort, the clinical interpretation is cautious awareness rather than formal contraindication.

AA Homozygous Risk Allele High Risk

Two copies of the CYP2C8 3'-UTR risk variant

CYP2C8 is expressed in vascular endothelium as well as liver. Its conversion of arachidonic acid to EETs contributes to coronary vasodilation and anti-inflammatory signalling. A 3'-UTR variant that reduces CYP2C8 expression would attenuate this endogenous cardioprotective effect, raising the steady-state risk of coronary events — consistent with the Rotterdam Study findings. The gene-sex interaction (stronger in males) may reflect differential steroid-hormone modulation of CYP2C8 expression, though the mechanistic pathway remains incompletely characterised. Because rs1058932 is not a coding-region allele, it is not captured by standard CPIC star-allele genotyping — making this variant an important addition for comprehensive pharmacogenomics panels.